We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.85B
AUM Growth
-$933M
Cap. Flow
-$365M
Cap. Flow %
-4.65%
Top 10 Hldgs %
37.02%
Holding
151
New
11
Increased
33
Reduced
26
Closed
20

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$137M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$91.8M
3
AET
Aetna Inc
AET
+$82.5M
4
HUM icon
Humana
HUM
+$78.7M
5
MRK icon
Merck
MRK
+$68M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$146M
2
MOH icon
Molina Healthcare
MOH
+$117M
3
ESRX
Express Scripts Holding Company
ESRX
+$102M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$89.8M
5
ABBV icon
AbbVie
ABBV
+$79.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.02%
2 Financials 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCR
76
DELISTED
CR Bard Inc.
BCR
$13M 0.17%
58,000
– –
DERM
77
DELISTED
Dermira, Inc.
DERM
$12.9M 0.16%
425,600
– –
LAB icon
78
Standard BioTools
LAB
$325M
$12.7M 0.16%
1,746,100
– –
EXAS
79
DELISTED
Exact Sciences
EXAS
$12.7M 0.16%
950,000
-151,600
-14% -$2.45M
IMGN
80
DELISTED
Immunogen Inc
IMGN
$12.4M 0.16%
6,095,647
– –
PTLA
81
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$12.4M 0.16%
551,500
+180,600
+49% +$3.53M
ALXN
82
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$12.2M 0.16%
+100,000
New +$12.2M
DBVT
83
DBV Technologies
DBVT
$803M
$12.1M 0.15%
34,570
– –
FWP
84
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$12M 0.15%
114,000
– –
VNDA icon
85
CALL
Vanda Pharmaceuticals
VNDA
$301M
$12M 0.15%
750,000
– –
RARE icon
86
Ultragenyx Pharmaceutical
RARE
$2.5B
$11.9M 0.15%
169,300
– –
PRQR icon
87
ProQR Therapeutics
PRQR
$243M
$11.3M 0.14%
2,305,446
– –
RCKT icon
88
Rocket Pharmaceuticals
RCKT
$334M
$11.3M 0.14%
462,325
– –
LLY icon
89
CALL
Eli Lilly
LLY
$1.09T
$11M 0.14%
150,000
-100,000
-40% -$7.45M
SEM
90
DELISTED
Select Medical
SEM
$11M 0.14%
+1,544,006
New +$10.7M
PVLA
91
Palvella Therapeutics
PVLA
$2B
$10.2M 0.13%
90,745
– –
NBRV
92
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$10M 0.13%
6,712
+1,452
+28% +$1.93M
ABT icon
93
Abbott
ABT
$191B
$9.43M 0.12%
245,400
-195,100
-44% -$7.74M
NUVA
94
DELISTED
NuVasive, Inc.
NUVA
$8.32M 0.11%
123,500
– –
STDY
95
DELISTED
SteadyMed Ltd
STDY
$7.99M 0.1%
3,072,196
– –
XENE icon
96
Xenon Pharmaceuticals
XENE
$6.17B
$7.7M 0.1%
1,000,000
– –
CRSP icon
97
CRISPR Therapeutics
CRSP
$4.63B
$7.54M 0.1%
+372,191
New +$6.96M
NERV icon
98
Minerva Neurosciences
NERV
$195M
$6.54M 0.08%
69,525
– –
TSRO
99
DELISTED
TESARO, Inc.
TSRO
$6.35M 0.08%
+47,200
New +$5.95M
SIEN
100
DELISTED
Sientra, Inc.
SIEN
$6.33M 0.08%
74,257
-17,493
-19% -$1.45M
2 3
4
5 6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2016 Portfolio in Review

As of Q4 2016, OrbiMed held 151 positions worth $7.85B, down 11% from $8.78B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed withdrew a net $365M in Q4 2016, closing 20 positions and reducing 26 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $146M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Elevance Health worth $147M.

  • OrbiMed's largest Q4 2016 buy was Elevance Health: 1,021,600 shares worth $147M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q4 2016, an estimated $91.8M increase.
  • OrbiMed's biggest Q4 2016 reduction was Molina Healthcare, cutting an estimated $117M.
  • OrbiMed fully exited Wellcare Health Plans, Inc. in Q4 2016, selling an estimated $146M.
  • OrbiMed's ten largest holdings make up 37% of its $7.85B portfolio in Q4 2016.
  • OrbiMed opened 11 new positions and closed 20 in Q4 2016.
  • OrbiMed's portfolio value fell 11% quarter-over-quarter to $7.85B.

Based on OrbiMed's 13F filing for Q4 2016, filed 14 Feb 2017.